Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid(GABA)-A receptors.Zuranolone was approved by the FDA as the first oral medication globally for the treatment of postpar-tum depression on August 4,2023.It reduced depression symptoms more significantly than placebo in women with severe postpartum depression.Zuranolone causes somnolence,dizziness,and sedation,therefore must be monitored throughout the therapy.This review summarizes the mechanism of action,pharmacokinetics,and clinical studies of zuranolone.
NETL
NSTL
万方数据
